Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SNSE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSensei Biotherapeutics reports Q1 2026 financial results
Filed May 15, 2026 · Period ending May 15, 2026 · ~1 min read
Key Changes
-
medium
Company announced financial results for the quarter ended March 31, 2026 via press release. Specific financial metrics are contained in the attached exhibit and not detailed in the 8-K body.
Item 2.02 verify on EDGAR → -
low
Press release dated May 15, 2026 attached as Exhibit 99.1. The 8-K filing itself provides no substantive details about the quarterly performance or any material developments.
Item 9.01 verify on EDGAR →
Summary
Sensei Biotherapeutics filed an 8-K on May 15, 2026 to announce its first quarter 2026 financial results for the period ending March 31, 2026. This is a routine quarterly earnings disclosure required for public companies. The filing itself contains minimal information, with the actual financial details and management commentary contained in the attached press release (Exhibit 99.1).
Retail investors should review the full press release to understand the company's Q1 performance, including revenue, expenses, cash position, and any updates on clinical programs or business developments. As a clinical-stage biotherapeutics company, key metrics to watch include cash runway, progress on drug candidates, and any changes to development timelines. The next quarterly report (Q2 2026) will be important to monitor for continued financial health and operational progress.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Sensei Biotherapeutics filed an 8-K attaching a press release dated May 15, 2026, with no material event details disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press Release of Sensei Biotherapeutics, Inc., dated May 15, 2026
The company attached a press release dated May 15, 2026 as Exhibit 99.1. The 8-K body does not disclose the content or subject matter of the press release, making it impossible to assess materiality from this filing alone.
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 15, 2026, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.
The company disclosed its financial results for the first quarter of 2026 ending March 31, 2026. The actual financial details are contained in the attached press release (Exhibit 99.1), which is not included in this 8-K body. This is a routine quarterly earnings announcement.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 25, 2026 · How we verify